Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 692

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 692
---
ANCE SHEETSAS OF DECEMBER 31, 2024 AND 2023(Currency expressed in United States Dollars (“US$”))(Audited)

    As of     December 31,  December 31,   Note  2024  2023 ASSETS         CURRENT ASSETS         Cash and bank balances     1,583,479   2,623,965 Fixed deposits placed with financial institutions (including $1,490,461 and $1,411,626 of fixed deposits with original maturities more than 3 months as of December 31, 2024 and 2023)     2,793,948   3,305,371 Trade receivables, net of allowance for credit losses of $517,877 and $1,307,508 as of December 31, 2024 and 2023 respectively (including $47,272 and $4,520 of trade receivables from related parties as of December 31, 2024 and 2023 respectively)  3   1,376,571   799,674 Other receivables, deposits and prepayments      203,660   122,432 Tax recoverable  4   84,167   57,588 Inventories (including goods in transit of $188,797 and $Nil as of December 31, 2024 and 2023 respectively)      1,388,624   1,137,770 Total current assets      7,430,449   8,046,800              NON-CURRENT ASSETS            Operating lease right-of-use assets  5   215,243   141,544 Property, plant and equipment, net  6   1,522,990   1,511,618 Investments in equity securities  7   1,265,166   1,699,831 Total non-current assets      3,003,399   3,352,993 TOTAL ASSETS     $10,433,848  $11,399,793              LIABILITIES AND STOCKHOLDERS’ EQUITY            CURRENT LIABILITIES            Trade payables (including $Nil and $21,953 of trade payables from related parties for December 31,